Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: A survey of centre strategies by the European Group for Blood and Marrow Transplantation

Bone Marrow Transplantation

Volumn 47, Issue 11, 2012, Pages 1459-1464

  Ruutu, T ^a   Van Biezen, A ^b   Hertenstein, B ^c   Henseler, A ^b   Garderet, L ^d   Passweg, J ^e   Mohty, M ^f,g   Sureda, A ^h   Niederwieser, D ⁱ   Gratwohl, A ^j   De Witte, T ^k  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c KLINIKUM BREMEN MITTE   (Germany)

^d HÔPITAL SAINT ANTOINE   (France)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f UNIVERSITÉ DE NANTES   (France)

^g NANTES UNIVERSITY HOSPITAL   (France)

^h ADDENBROOKE S HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^j UNIVERSITY HOSPITAL BASEL   (Switzerland)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

allogeneic stem cell transplantation; graft versus host disease; prophylaxis; treatment

Indexed keywords

ALEMTUZUMAB; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; EVEROLIMUS; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL PROTOCOL; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG DOSE REDUCTION; HEALTH CARE FACILITY; HEALTH CARE POLICY; HEALTH SURVEY; HISTOCOMPATIBILITY; HUMAN; MAJOR CLINICAL STUDY; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; PROPHYLAXIS; PUVA; REDUCED INTENSITY CONDITIONING; T CELL DEPLETION; TREATMENT DURATION; TREND STUDY;

DATA COLLECTION; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84869082702     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.45     Document Type: Article

References (13)

1. Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009; 116: 4715-4726.
2. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997; 19: 759-764. (Pubitemid 27207889)
3. Bacigalupo A, van Lint MT, Occhini D, Gualandi F, Lamperelli T, Sogno G et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77: 1423-1428.
4. Locatelli F, Zecca M, Rondelli R, Bonetti F, Dini G, Prete A et al. Graft versus host disease prophylaxis with low dose cyclosporine reduces the risk of relapse in children with acute leukemia given HLA identical sibling bone marrow transplantation: results of a randomized trial. Blood 2000; 95: 1572-1579. (Pubitemid 30120815)
5. Bacigalupo A. Management of acute graft-versus-host disease. Br J Haematol 2007; 137: 87-98. (Pubitemid 46474711)
6. Ferrara JLM, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373: 1550-1561.
7. Inamoto Y, Flowers MED, Lee SJ, Carpenter PA, Warren EH, Deeg J et al. Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation. Blood 2011; 118: 456-463.
8. Ljungman P, Bregni M, Brune M, Cornelissen J, de Witte T, Dini G et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplant 2010; 45: 219-234.
9. Goldman J. Special report: bone marrow transplants using volunteer donors, recommendations and requirements for a standardized practice throughout the world-1994 update. Blood 1994; 84: 2833-2839.
10. World Marrow Donor Association International standards for unrelated hematopoietic stem cell donor registries. www.worldmarrow.org,-Standards- December-2007.pdf.
11. Clift RA, Buckner CD, Appelbaum FA, Bearman SI, Petersen FE, Fisher LD et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. Blood 1990; 76: 1867-1871.
12. Pavlü J, Szydlo RM, Goldman JM, Apperley JF. Three decades of transplantation for chronic myeloid leukemia: what have we learned? Blood 2011; 117: 755-763.
13. Frassoni F, Labopin M, Powles R, Mary J-Y, Arcese W, Bacigalupo A et al. Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Lancet 2000; 355: 1393-1398. (Pubitemid 30215961)